FAIRFIELD, N.J., June 7, 2012 /PRNewswire/ -- Aperture Health, Inc. (OTC APRE) is aggressively pursuing and seeking out the newly emerging Accountable Care Organizations ("ACOs") business models and offering the services of Triad Therapeutics, its wholly owned subsidiary, to help with effective transitions of care to the home setting for patients needing IV services, as well as, the intent to provide Medication Therapy Management Services ("MTM") at home.

The ACO is an exciting new form of provider derived via a collaborative approach between hospitals, physicians and ancillary health providers, including but not limited to, homecare and home IV therapy service providers.  Moreover, the ACO model is being heavily promoted by the Centers for Medicare and Medicaid Services ("CMS") via mandating the bundling of payments as a measure to advance care quality, and as a means to improve clinical outcomes and contain skyrocketing healthcare costs.  In the future, ACOs will develop and implement quality metrics, implement widespread healthcare information technology usage and aggregate lifesaving and helpful data with the combined service providers with the goal to present regular patient outcomes and reporting which will effectively monitor and assess cost savings to the healthcare system.  Accordingly, APRE believes it can serve an integral function for  ACOs in achieving their primary goal, which most notably includes creating a patient-centered transition of care process that will result in decreased hospital readmissions and improved patient quality of life through establishment of a chronic disease state management program to focus on containing some of the largest drivers of healthcare costs.

James Hennig, R.Ph, Chief Executive Officer and Chairman of the Board of Directors commented, "We are extremely excited to be doing business in the ever-growing field of home health care and IV therapy. The advent of the cost effective ACO business model in healthcare brings even more focus on the need to provide quality transitions of patient care from hospital to home. By combining hi-tech nursing, clinical pharmacy, and medication management services coupled with streamlined communication to all medical providers, we can help any ACO reach the goal of high quality continuity of care while being a catalyst for reducing healthcare costs."

About Aperture Health, and Triad Therapeutics

Aperture Health through its wholly owned subsidiary Triad Therapeutics operates a fully JCAHO accredited home IV therapy company, achieving this "gold standard" status in 2007. The company has built a well respected reputation in its industry for its therapy expertise and commitment to care for its patient clients. The company services clients throughout the States of New Jersey, New York and Connecticut, providing opportunity for organic growth. Triad's full time marketing and sales personnel continuously represent the company in the core services areas, growing and maintaining the company's referral source base. Patient referrals are made from physicians, hospitals, insurance companies, veterinarians and hospice care providers that have established a professional rapport with Triad.

Safe Harbor

Certain statements in this news release are forward-looking, including (without limitation) growing revenues and earnings, expected results from current projects and attracting new business.  Undue reliance should not be placed on such forward-looking statements because the matters they describe are subject to known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond the Company's control. The Company's actual results, performance and trends could differ materially from those indicated or implied by such statements as a result of various factors, including (without limitation) the continued strengthening of Triad's selling and marketing functions, continued customer satisfaction, contract renewal, new product development, continued availability of capable dedicated personnel, continued cost management, success and availability of acquisitions, availability of financing and other factors, as well as by factors applicable to most companies such as general economic, competitive and other business and civil conditions.  Information regarding certain of those and other risk factors and cautionary statements that could affect future results, performance or trends is discussed in the Company's OTC Disclosure Statement and unaudited management financials posted on www.pinksheets.com .  All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.  The information set forth herein speaks only as of the date hereof.

 

SOURCE Aperture Health, Inc.

Copyright 2012 PR Newswire

Elinx (CE) (USOTC:ELNX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse Elinx (CE)
Elinx (CE) (USOTC:ELNX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Elinx (CE)